Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24075608 | 0.85 | AAK1 (0.43) | AAK1SYKTRPA1ATMLMNA | |
| SCHEMBL31028286 | 0.84 | P2RY2 (0.44) | AAK1ATMCTSKHPGDKDM4E | |
| SCHEMBL28821334 | 0.84 | ITGB3 (0.43) | AAK1CTSKITGB3ITGA2B | |
| SCHEMBL31028291 | 0.80 | AAK1 (0.43) | AAK1SYKTRPA1ATMSMN1; SMN2 | |
| SCHEMBL31028283 | 0.80 | AAK1 (0.43) | AAK1SYKTRPA1ATMSMN1; SMN2 | |
| SCHEMBL31028296 | 0.79 | AAK1 (0.47) | AAK1SYKLMNASMN1; SMN2KDM4E | |
| SCHEMBL24075373 | 0.78 | LTA4H (0.36) | LMNASMN1; SMN2HPGDNPC1RAB9A | |
| SCHEMBL31028273 | 0.76 | LMNA (0.36) | AAK1SYKLMNASMN1; SMN2 | |
| SCHEMBL24074705 | 0.74 | MAPT (0.40) | SMN1; SMN2HPGDNPC1RAB9AKDM4E | |
| SCHEMBL24075383 | 0.73 | TDP1 (0.45) | SYKATMCTSKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371434-B2 | MLL1 inhibitors and anti-cancer agents | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2025-07-29 | — | — | US | disclosed |
| EP-4013754-B1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2024-07-24 | — | — | EP | disclosed |
| WO-2021239077-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371434-B2 | MLL1 inhibitors and anti-cancer agents | MLLT1, BMI1, DOT1L | AAK1 1076/4885SYK 2571/4885TRPA1 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.